Universität Wien FIND
Achtung! Das Lehrangebot ist noch nicht vollständig und wird bis Semesterbeginn laufend ergänzt.

323105 VU Innovation & Leadership in Preclinical Drug Development - MPS5 (2020S)

2.00 ECTS (1.00 SWS), SPL 32 - Pharmazie
Prüfungsimmanente Lehrveranstaltung

Details

Sprache: Englisch

Lehrende

Termine

Di & Mi. 03.03 & 04.03 17.00 – 18.30 Uhr s.t.
Mo. 20.04 17.00 – 19.00 Uhr s.t.
je. Di. 10.03, 31.03, 05.05, 12.05+ 17.00 – 19.00 Uhr s.t.
je. Mi. 11.03, 01.04 17:00 – 19.00 Uhr s.t.
je. Do. 05.03, 23.04, 07.05, 14.05* 17.00 – 19.00 Uhr s.t.
*Final Evaluation: Required attendance
+Optional session on 12.05.


Information

Ziele, Inhalte und Methode der Lehrveranstaltung

This course will introduce the concepts of disruptive innovation, leadership for innovation projects, and development of effective persuasive communication/presentation techniques. We will review exemplary innovators in the health care and technology industries, explore leadership concepts involving self-awareness and awareness of others, and develop skills for creative problem solving needed to successfully navigate innovation projects that are useful not only in the context of innovation but also important for developing skills needed for professional life. Armed with this knowledge, participants will forms teams, identify a challenge related to drug discovery for which they will design an innovative solution and present a pitch to convince others that their idea is worth adopting. The challenge will provide a framework and context to: 1) explore the unique leadership competencies needed to guide and shape creative teams, 2) inspire the imagination needed to formulate and recognize a good idea, and further transform it into an innovation, and 3) develop a strategy to present and communicate effectively and persuasively.
This course is in English and fulfills 2 ECTS.
An experiential learning method allows students to apply concepts covered in class to real situations.
- Laptops, tablets, phones or other devices that will enable you to search the internet and gather information for your projects and class discussion are allowed and encouraged in this class. Please bring these items to class if you have them.

Art der Leistungskontrolle und erlaubte Hilfsmittel

1. Attendance & Participation: participants are expected to attend all course sessions and actively participate in the course.
2. Three team oral presentations and exercises to be handed in as outlined during the course.

Mindestanforderungen und Beurteilungsmaßstab

-Class attendance.
-Active participation in class and with team.
-Hand in assignments as outlined in class, e.g., presentations, leadership self-assessment exercises, team profiles.
- Three (3) oral presentations (team effort).
Final Presentation (3rd)- Final evaluation. Presentation of pitch and early stage solution design concept (team effort).

Prüfungsstoff

Required Final Assignment - Oral presentation with a developed story line (Pitch), and a primitive prototype design (early stage mock-up of the design concept) [team effort]. Presentation to be submitted by email (PPT, KEY or OpenOffice formats) before it is given orally. Content and requirements to be discussed in class.

Literatur

Recommended Reading (optional):
1. Ross, Alec. The Industries of the Future. Simon & Schuster, 2016.
2. Kelley, Tom. The Art of Innovation. New York: Doubleday, 2005.
3. Gallo, Carmine. The Innovation Secrets of Steve Jobs. New York: McGraw-Hill, 2011, 31.
4. Vise, David & Mark Malseed. The Google Story. New York: Dela- corte Press, 2005, 256.
5. John Battelle. The Search: How Google and Its Rivals Rewrote the Rules of Business and Transformed Our Culture. New York: Penguin Group, 2005, 141.
6. Objectified. Jonathan Ive, https://www.youtube.com/watch?v=nUHROAtyGIg
7. Dyer, Jeff, Hal Gregersen & Clayton M. Christiansen. The Innovator’s DNA. Boston, MA: Harvard Business School Press, 2011.
8. Christensen, Clayton M. & Michael Raynor. Innovator’s Solution. Boston, MA: Harvard Business School Press, 2003.
9. Christensen, Clayton M. The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail. Boston, MA, Harvard Business School Press, 1997.
10. Christensen, Clayton M. Meeting the Challenge of Disruptive Change. Harvard Bus. School Press, 1997.
11. “The Life and Work of Dr. Paul." https://www.janssen.com/belgium/life-and-work-dr-paul
12. Pfeiffer, KP et al., Country Brief: Austria. eHealth Strategies. Bonn/Brussels. Oct. 2010.
http://ehealth-strategies.eu/database/documents/Austria_CountryBrief_eHStrategies.pdf
13. Abou-Gharbia, M. & Childers, W.E. Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 1. Criticisms Faced by the Pharmaceutical Industry. J. Med. Chem. (2016):56, 5659.
14. Brown, Tim. Design Thinking. Harvard Business Review (2008), 84.
15. Mottl, J. Why today’s smartphones may be the only tech patients need. 13 December 2014. Available from: h p://www. ercemobilehealthcare.com/story/why-todays-smartphones- may-be-only-wearables-pa ents-need/2014-12-13.
16.Elvidge, S. Footfalls & Heartbeats: Smart knitted textiles for quanti ed self and patient monitoring Start-Up, 17 December 2013. https://www.innovationintextiles.com/footfalls-heartbeats-launches-crowdfunding-campaign-to-produce-smart-knitted-fabrics/
17. Szcerba, R.J. No Donor Required: 5 Body Parts You Can Make With 3-D Printers. Forbes, 17June 2016. https://www.forbes.com/sites/robertszczerba/2015/06/17/no-donor-required-5-body-parts-you-can-make-with-3-d-printers-2/#
18. Szczerba, R.J. Why Mobile Health Technologies Haven’t Taken Off (Yet). Forbes, 16 July 2014. https://www.forbes.com/sites/robertszczerba/2014/07/16/why-mobile-health-technologies-havent-taken-off-yet/#2bfcf73076ed

Zuordnung im Vorlesungsverzeichnis

Letzte Änderung: Fr 07.02.2020 00:05